Bitterman Kevin sold $135K of IRON (indirect holdings)
Bitterman Kevin sold 1,689 indirectly-held shares of Disc Medicine, Inc. (IRON) at $79.96 ($0.14M total) across 3 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest in size and unlikely to move the stock materially, but it adds to the flow of insider activity data used by quantitative models.
Market read
Primary relevance is to traders monitoring insider transactions; limited broader market effect.
What to watch
Potential upcoming clinical data releases that may have prompted the pre‑arranged sale.
Background
Form 4 filing by Disc Medicine Inc. (ticker IRON) discloses a director's sale under a pre‑arranged 10b5‑1 plan.
Ticker impact
Director Kevin Bitterman sold 1,689 shares for $135K via a 10b5‑1 plan, reducing his stake to 13,427 shares.
minor downward pressure, likely within normal volatility range
The transaction is a routine 10b5‑1 sale of a small dollar amount for a micro‑cap biotech; markets typically view such sales as low‑impact unless unusually large.
Market effects
Minimal effect on the biotech sector; similar insider sales are common.
No regional impact; company is US‑listed.
Limited to investors tracking insider activity in small‑cap biotech.
Counterpoint
The sale could be a tax‑planning move rather than a negative signal.
Key entities
- companyDisc Medicine, Inc.
US‑listed biotech company (ticker IRON).
- personKevin Bitterman
Director of Disc Medicine who sold shares.
